Related Experiment Video
Updated: Apr 30, 2026

Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes hPSC-CMs Using Multi-electrode Arrays MEAs
Published on: May 12, 2017
Integrating high-fidelity hiPSC-cardiomyocytes with AI-driven modeling for enhanced proarrhythmic risk assessment
Su-Bin Kim1, Jaehun Lee1, Jieun An1
1Department of Commercializing iPSC Technology, NEXEL Co., Ltd., 8th floor, 55 Magokdong-Ro, Gangseo-Gu, Seoul, 07802, Republic of Korea.
Insights
This study introduces an AI-powered platform using human stem cell-derived cardiomyocytes to accurately predict drug-induced heart risks. The system effectively identifies cardiotoxicity missed by traditional assays, improving drug safety screening.
Area of Science:
- Cardiovascular toxicology
- Stem cell biology
- Artificial intelligence in drug discovery
Background:
- Drug-induced cardiotoxicity is a major cause of drug failure, with current prediction methods being suboptimal.
- Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a human-relevant model aligning with regulatory guidelines (CiPA, ICH E14/S7B).
Purpose of the Study:
- To validate an integrated platform combining hiPSC-CMs and AI for enhanced prediction of drug-induced proarrhythmic risk.
- To assess the platform's ability to detect functional cardiotoxicity often missed by standard assays.
Main Methods:
- Phenotypic characterization of hiPSC-CMs for cardiac differentiation efficiency and cell identity.
- Electrophysiological data collection from 28 CiPA reference compounds using Multielectrode Array (MEA).
- Training and evaluation of machine learning models, including Artificial Neural Networks, for risk prediction.
Main Results:
- The AI-hiPSC-CM platform achieved a high predictive accuracy (ROC-AUC of 0.982) using an Artificial Neural Network.
- The platform identified functional cardiotoxicity (FPDcF prolongation) in anticancer agents (sunitinib, erlotinib) that lacked overt structural cytotoxicity.
- These agents were classified as high-to-intermediate risk for Torsades de Pointes (TdP), quantifying time-dependent liabilities.
Conclusions:
- The validated AI-hiPSC-CM platform accurately detects hidden functional cardiotoxicity, improving upon traditional methods.
- This integrated system serves as a high-throughput, early-stage safety screening tool, bridging in vitro findings with clinical outcomes.
- The platform provides a standardized framework for assessing drug-induced proarrhythmic risk, enhancing drug development safety.
Abstract:
Cardiotoxicity remains the leading driver of drug attrition; however, its prediction remains suboptimal when conventional hERG assays and animal models are used. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a human-relevant alternative that aligns with the CiPA initiative and ICH E14/S7B guidelines. This study validated an integrated platform that combines high-purity hiPSC-CMs with Artificial Intelligence (AI) to enhance the accuracy of predicting drug-induced proarrhythmic risk. Phenotypic characterization of the hiPSC-CMs demonstrated high cardiac differentiation efficiency (cTnT + > 95%) and a predominant ventricular-like identity (MLC-2 V + , 78-84%), ensuring biological relevance for ventricular arrhythmia assessment. Electrophysiological data from 28 CiPA reference compounds were collected via Multielectrode Array (MEA) to train multiple machine learning models. The Artificial Neural Network outperformed the other architectures, achieving a superior ROC-AUC of 0.982. The utility of the platform was evaluated using 12 anticancer agents. Although most drugs showed dose-dependent reductions in impedance-based viability, four compounds (Idarubicin, Erlotinib, Sunitinib, Cyclophosphamide) did not exhibit overt structural cytotoxicity. However, MEA analysis revealed significant functional perturbations, including FPDcF prolongation, in sunitinib- and erlotinib-treated samples after long-term treatment. The AI model subsequently classified these two agents as high-to-intermediate risk for Torsades de Pointes (TdP), thereby quantifying their time-dependent proarrhythmic liabilities. These findings show the platform's ability to detect hidden functional cardiotoxicity, often missed by standard viability assays. The AI-hiPSC-CM system offers a high-throughput, early-stage safety screening tool that bridges in vitro data and clinical outcomes with a standardized risk assessment framework.
More Related Videos
10:30Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Published on: August 4, 2022
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022